Clinical Trial Update: TIL Therapy Combined With Pembrolizumab for Advanced or Metastatic Refractory Stomach and Esophageal Cancer [Phase 1, Phase 2]

View source ↗

Summary

This clinical trial update describes a Phase 1/2 study evaluating the combination of tumor-infiltrating lymphocyte (TIL) therapy with pembrolizumab in advanced …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Esophageal Cancer
• Stomach Cancer

Drugs mentioned

• KEYTRUDA (PEMBROLIZUMAB)
• TIL therapy (tumor-infiltrating lymphocyte therapy)

Snippet

Sponsor: Essen Biotech | Conditions: Stomach Cancer, Stomach Cancer Recurrent | Phase 1, Phase 2 | Status: RECRUITING